I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450

Service as led to the 2 5 2005 ox 450,

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT Examining Group 1614 Patent Application Docket No. USF-T195XC1 Serial No. 10/764,728

on May 23, 2005

Jenna M. Morrison, Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

(Not yet assigned)

Art Unit

1614

Applicants

Q. Ping Dou, Tak-Hang Chan, David M. Smith

Serial No.

10/764,728

Filed

January 26, 2004

For

Polyphenol Proteasome Inhibitors, Synthesis, and Methods of Use

MS AMENDMENT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Jenna M. Morrison
Patent Attorney

Registration No. 55,468

Phone No.:

352-375-8100

Fax No.:

352-372-5800

Address:

P.O. Box 142950

Gainesville, FL 32614-2950

JMM/mv

Attachments: Form PTO/SB/08 (1 page); copies of references cited therein.

J:\USF\T195XCI\PTO\IDS.pto.doo/DNB/mv

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB Under the control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of 1 1

Complete if Known		
Application Number	10/764,728	
Filing Date	January 26, 2004	
First Named Inventor	Q. Ping Dou	
Group Art Unit	1614	
Examiner Name		
Attorney Docket Number	USF-T195XC1	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	CHEN, C. et al. "Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death" <i>Arch. Pharm. Res.</i> , 2000, 23(6):605-612.	
	R2	CHUNG, J.Y. et al. "Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3'-digallate" FASEB J., 2001, 15:2022-2024.	
	R3	MASUDA, M. et al. "Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines" Clin. Cancer Res., 2001, 7:4220-4229.	
	R4	YANG, C.S. and WANG, Z-Y "Tea and Cancer" <i>J. Natl. Cancer Inst.</i> , 1993, 85(13):1038-1049.	
	R5	YU, R. et al. "Activation of mitogen-activated protein kinases by green tea polyphenols: potential signaling pathways in the regulation of antioxidant-responsive element-mediated Phase II enzyme gene expression" <i>Carcinogenesis</i> , 1997, 18(2):451-456.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		T
	R12		
	R13		Щ

Examiner	Date
Signature	Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO) and optionally applicable. to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.